Blackstone-backed biotech launches with up to $300M for immune drug

May 15, 2024


TSLP has become a popular target for drugmakers looking for new ways to tackle inflammation. Amgen and AstraZeneca entered the market first, after winning Food and Drug Administration approval in late 2021 for the asthma treatment Tezspire, an injection designed to be administered every four weeks.

Two startups in recent years have caught the eye of investors with TSLP-targeted drugs they say have unique advantages. Upstream Bio launched in 2022, raised new funds in 2023 and this year announced the start of a Phase 2 clinical trial in severe asthma that’s testing dosing of the company’s drug at 12-week and 24-week intervals.

Read More on Biopharma Dive